ADC / XDC

Delve into the world of ADC / XDC in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on ADC / XDC to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

GenSci's Inhaled siRNA GenSci117 Targeting MMP7 Clears NMPA Registration Clinical Trial Acceptance – A Class 1 RNAi Candidate for Idiopathic Pulmonary Fibrosis
CompanyDrug

GenSci’s Inhaled siRNA GenSci117 Targeting MMP7 Clears NMPA Registration Clinical Trial Acceptance – A Class 1 RNAi Candidate for Idiopathic Pulmonary Fibrosis

Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that the registration clinical trial application for GenSci117 inhalation powder, developed by its subsidiary Changchun Genescience Pharmaceutical Co., Ltd.…

Qyuns Therapeutics Out‑Licenses TL1A × IL‑17 Bispecific Program to Caldera Therapeutics – USD 30 Million Upfront with Up to USD 750 Million in Milestones

Qyuns Therapeutics Out‑Licenses TL1A × IL‑17 Bispecific Program to Caldera Therapeutics – USD 30 Million Upfront with Up to USD 750 Million in Milestones

Zai Lab Reports Q3 2026 Revenue of USD 108.2 Million – Nuzyra and New Launches Offset Optune Decline as USD 250 Million ADS Private Placement Closes

Zai Lab Reports Q3 2026 Revenue of USD 108.2 Million – Nuzyra and New Launches Offset Optune Decline as USD 250 Million ADS Private Placement Closes

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Transcenta Presents Promising Pre-clinical Data for Proprietary LIV1 Antibody-Drug Conjugate at AACR 2026

CompanyDrug

Gan & Lee’s Nectin-4 ADC GLR1059 Clears Regulatory Hurdle for Solid Tumor Trials

Daiichi Sankyo and AstraZeneca Launch Datroway ADC in China for HR-Positive, HER2-Negative Breast Cancer
CompanyDrug

Daiichi Sankyo and AstraZeneca Launch Datroway ADC in China for HR-Positive, HER2-Negative Breast Cancer

CompanyDrug

Hengrui’s Trastuzumab Rezetecan Receives CDE Breakthrough Therapy Designation for First-Line HER2+ Metastatic Breast Cancer in Combination with Pertuzumab

CompanyDrug

FDA Grants Priority Review to Merck, Astellas, and Pfizer’s sBLA for Padcev-Pembrolizumab Combo in Perioperative Muscle-Invasive Bladder Cancer

CompanyDrug

Hansoh Pharmaceutical Presents Promising Phase I Data for B7-H3 ADC Risvutatug Rezetecan Combined with Adebrelimab at AACR 2026 – 47.1% ORR and 14.0-Month PFS in Solid Tumors

CompanyDrug

Hansoh Pharma’s B7-H3 ADC HS-20093 Secures Fourth NMPA Breakthrough Therapy Designation for NSCLC Combination Therapy

CompanyDrug

Hengrui Pharma’s Nectin-4 ADC SHR-A2102 Granted Second NMPA Breakthrough Therapy Designation for Cervical Cancer

Show More